Solventum Co. (NYSE:SOLV) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 3.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,149,198 shares of the company's stock after selling 36,263 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.67% of Solventum worth $75,916,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in SOLV. Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Solventum in the 3rd quarter valued at approximately $125,488,000. Trian Fund Management L.P. lifted its holdings in Solventum by 32.9% in the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company's stock valued at $496,842,000 after acquiring an additional 1,765,676 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Solventum during the 3rd quarter worth $50,948,000. Nordea Investment Management AB increased its holdings in Solventum by 189.5% in the fourth quarter. Nordea Investment Management AB now owns 659,887 shares of the company's stock valued at $43,902,000 after buying an additional 431,986 shares in the last quarter. Finally, KBC Group NV boosted its stake in shares of Solventum by 725.3% during the 4th quarter. KBC Group NV now owns 234,933 shares of the company's stock worth $15,520,000 after acquiring an additional 206,466 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Bank of America lifted their price objective on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Wednesday, February 26th. The Goldman Sachs Group increased their target price on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday, March 3rd. Mizuho boosted their price target on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Wells Fargo & Company raised their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. Finally, Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $79.86.

Remove Ads

Solventum Trading Up 2.8 %

Shares of NYSE SOLV traded up $2.01 during trading on Friday, hitting $74.31. 1,142,865 shares of the company traded hands, compared to its average volume of 1,434,765. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $12.85 billion and a P/E ratio of 27.02. The company has a 50-day moving average price of $74.37 and a 200-day moving average price of $70.97. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.